Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: Two case studies

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 984-995

  Soto, Elena ^a,g   Keizer, Ron J ^b,g   Trocóniz, Iñaki F ^a   Huitema, Alwin D R ^b,d   Beijnen, Jos H ^b,c,d   Schellens, Jan H M ^c,d   Wanders, Jantien ^e   Cendrós, Josep María ^f   Obach, Rosendo ^f   Peraire, Concepción ^f   Friberg, Lena E ^g   Karlsson, Mats O ^g  

^a UNIVERSITY OF NAVARRA   (Spain)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e EISAI CO LTD   (Japan)

^f IPSEN   (France)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Diflomotecan; Indisulam; Neutropenia; NONMEM; Semi mechanistic model

Indexed keywords

ANTINEOPLASTIC AGENT; DIFLOMOTECAN; INDISULAM; CAMPTOTHECIN; DRUG DERIVATIVE; N (3 CHLORO 7 INDOLYL) 1,4 BENZENEDISULPHONAMIDE; N-(3-CHLORO-7-INDOLYL)-1,4-BENZENEDISULPHONAMIDE; SULFONAMIDE;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CALCULATION; CASE STUDY; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; SEMI MECHANISTIC MODEL; SIMULATION; BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG DEVELOPMENT; LEUKOCYTE COUNT; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PREDICTIVE VALUE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG DISCOVERY; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84856077668     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9437-z     Document Type: Article

References (34)

1. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524-4531. doi:10.1200/JCO.2003.05.002
2. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K (1998) Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64:511-521. doi:10.1016/S0009-9236 (98) 90134-5
3. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ (2001) Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7:2301-2308
4. Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF (2003) A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186:29-41
5. Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z (2005) The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol 234:311-327. doi:10.1016/j.jtbi.2004.11.026
6. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63:1035-1048. doi:10.1007/s00280-008-0828-1
7. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721
8. Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76:567-578. doi:10.1016/j.clpt.2004.08.008
9. van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23:225-234. doi:10.1007/s10637-005-6730-3
10. Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57:727-735. doi:10.1007/s00280-005-0112-6 [doi]
11. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57:412-426. doi:10.1007/s00280-005-0077-5 [doi]
12. Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97:290-296. doi:10.1038/sj.bjc.6603872
13. Kathman SJ, Williams DH, Hodge JP, Dar M (2007) A Bayesian population PK-PD model of ispinesib-induced myelosuppression. Clin Pharmacol Ther 81:88-94. doi:10.1038/sj.clpt.6100021
14. Brain EG, Rezai K, Lokiec F, Gutierrez M, Urien S (2008) Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study. Br J Clin Pharmacol 65:607-610. doi:10.1111/j.1365-2125.2007.03095.x
15. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR (2008) Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 14:5856-5863. doi:10.1158/1078-0432. CCR-08-1046
16. Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, Friberg LE (2009) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosup-pression. Cancer Chemother Pharmacol. doi:10.1007/s00280-009-1089-3
17. Friberg LE, Sandstrom M, Karlsson MO (2009) Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs. doi:10.1007/s10637-009-9308-7
18. Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD (2009) Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Invest New Drugs. doi:10.1007/s10637- 008-9216-2
19. Graham JS, Falk S, Samuel LM, Cendros JM, Evans TR (2009) A multi-centre dose-escalation and pharmacokinetic study of diflomo-tecan in patients with advanced malignancy. Cancer Chemother Pharmacol 63:945-952. doi:10.1007/s00280- 008-0795-6
20. Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC (1999) Homocampto-thecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 59:2939-2943
21. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42:3789-3799
22. Raymond E, ten Bokkel Huinink WW, Taieb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH, European Organization for the Research and Treatment of Cancer Early Clinical Study Group (2002) Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 20:3508-3521
23. Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Prunonosa J, Principe P, Twelves C (2003) Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 9:4101-4107
24. Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C (2007) A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol 18:569-575. doi:10.1093/annonc/mdl439
25. Punt CJ, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M (2001) Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol 12:1289-1293
26. Terret C, Zanetta S, Roche H, Schellens JH, Faber MN, Wanders J, Ravic M, Droz JP, EORTC Early Clinical Study Group (2003) Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 39:1097-1104
27. Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P (2003) Phase I and pharmaco-kinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 9:5195-5204
28. Van Kesteren C, Mathot RA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH, Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer (2002) Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20:4065-4073
29. Beal SL, Sheiner LB (1989-2006) NONMEM users guides. Icon development solutions, Ellicot City, Maryland, USA.
30. Schoemaker RC, van Gerven JM, Cohen AF (1998) Estimating potency for the Emax-model without attaining maximal effects. J Pharmacokinet Biopharm 26:581-593
31. Karlsson M, Holford NH (2008) A tutorial on visual predictive checks. Available: www.page-meeting.org/?abstract=1434.
32. Zandvliet AS, Schellens JH, Dittrich C, Wanders J, Beijnen JH, Huitema AD (2008) Population pharmacokinetic and pharma-codynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66:485-497. doi:10.1111/j.1365-2125. 2008.03230.x
33. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD (2008) PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829-839. doi:10.1038/sj.clpt.6100344
34. Dansirikul C, Silber HE, Karlsson MO (2008) Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn 35:269-283. doi:10.1007/s10928-008-9088-2